Martin Carlsson
Pfizer (United States)(US)
Publications by Year
Research Areas
Urinary Bladder and Prostate Research, Pelvic floor disorders treatments, Urinary Tract Infections Management, Growth Hormone and Insulin-like Growth Factors, Amyloidosis: Diagnosis, Treatment, Outcomes
Most-Cited Works
- → Tolterodine and Tamsulosin for Treatment of Men With Lower Urinary Tract Symptoms and Overactive Bladder(2006)511 cited
- → Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head‐to‐head placebo‐controlled trial(2009)159 cited
- → Safety and Efficacy of Pediatric Growth Hormone Therapy: Results From the Full KIGS Cohort(2022)104 cited
- → Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head‐to‐head, placebo‐controlled trial(2010)99 cited
- → Estimating a Minimally Important Difference in Pulmonary Arterial Hypertension Following Treatment With Sildenafil(2008)86 cited
- → Extended‐release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score(2008)79 cited
- → Myocardial Contraction Fraction by M-Mode Echocardiography Is Superior to Ejection Fraction in Predicting Mortality in Transthyretin Amyloidosis(2018)63 cited
- → Symptom-specific efficacy of tolterodine extended release in patients with overactive bladder: the IMPACT trial(2006)59 cited
- → A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder(2009)58 cited
- → Optimal Thresholds by Maximizing or Minimizing Various Metrics via ROC-Type Analysis(2013)52 cited